Atreca Inc (OTCPK:BCEL)
$ 0.09553 0.01053 (12.39%) Market Cap: 3.79 Mil Enterprise Value: -16.74 Mil PE Ratio: 0 PB Ratio: 0.35 GF Score: 0/100

Atreca Inc at Cowen IO Next Summit (Virtual) Transcript

Nov 11, 2022 / 07:40AM GMT
Release Date Price: $1.48 (+4.23%)
Phil Nadeau
Cowen Inc. - Analyst

Good afternoon, and welcome once again to Cowen & Company's IO Next Summit. I'm Phil Nadeau, a biotech analyst here at Cowen, and it's my pleasure to moderate the next session with Atreca. We have from Atreca John Orwin, Tito Serafini, Steven Gould, and Alex Gray.

We'll jump right into the questions and maybe start with the discussion of ATRC-101, maybe just a brief background. Tito, for those less familiar, you could give a brief introduction to 101, summarize this preclinical data, and its mechanism of action.

Tito Serafini
Atreca, Inc. - Chief Strategy Officer

Sure. Thanks, Phil, for having us here today to chat about Atreca. So the 101 is our most advanced program. The target is a ribonucleoprotein complex that's tumor specific 101 and came from our platform. This complex was discovered by virtue of our discovering the antibody we engineered into 101.

It's mechanism of action involves binding to this ribonucleoprotein complex and then delivering that complex to the innate immune system cells present

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot